… THRX ) for 21% of royalty that it gets from GlaxoSmithKline plc ( GSK ). At the heart of the deal are four COPD (chronic ..... future royalties that Theravance will receive from GlaxoSmithKline from sale of four COPD drugs. One out of the four …
… Fabry disease, and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease. Amicus and its partner GlaxoSmithKline ( GSK ) are conducting two Phase 3 global studies (Study 011 and Study 012) of oral migalastat HCl monotherapy in …
… profiles. Amgen launched platelet booster Nplate in 2008, a high-priced biologic that is competing well with GlaxoSmithKline 's GSK Promacta. Most importantly, Amgen also received FDA approval for denosumab (marketed as Prolia in osteoporosis …
… board members are highly qualified; for example, David Stout acted as president of pharmaceutical operations at GlaxoSmithKline . Shire is an Ireland-based specialty biopharmaceutical firm, recently reorganized into six business units: rare …
… announced that it intends to pay $1 billion to Theravance for a 21% stake in its royalty stream from partner GlaxoSmithKline GSK on four respiratory disease products. We are maintaining our fair value estimate as we await additional announcements …
… for a 21% participation interest in future royalty payments from THRX's four respiratory collaborations with GlaxoSmithKline ( GSK ) including the recently-approved Breo Ellipta/Relvar treatment for COPD. The news comes on the heels of …
DUBLIN, May 13 (Reuters) - Elan Corporation PLC : * Buys 21 percent of Royalty Theravance receives from GlaxoSmithkline
GlaxoSmithKline ( GSK +1.5% ) and Theravance ( THRX +11% ) both move higher today after the FDA approves Breo Ellipta for the treatment of airflow …
… development operation. In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by market ..... the world's largest pharmaceutical companies, GlaxoSmithKline has used its vast resources to create the next generation …
… Regarding management background, Viehbacher brings strong management credentials with 20 years of experience at GlaxoSmithKline in finance and general management. In addition, Viehbacher ran Glaxo's French business operations in the mid …